New hope for lymphoma patients: experimental drug epcoritamab enters phase 2 trial
NCT ID NCT06796998
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the investigational drug epcoritamab can help people with newly diagnosed marginal zone lymphoma, a slow-growing blood cancer. About 25 adults will receive the drug and be monitored for complete remission after 12 cycles. The goal is to see if this treatment can control the disease effectively.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can 3D-Printed models unlock personalized blood cancer therapies?
- Can donor immune cells be engineered to fight blood cancer?
- Can a targeted drug boost standard therapy for a rare lymphoma?
- Smartwatches track hidden heart risk in blood cancer patients